Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBM-H901 gene therapy in hemophilia B
CTR20212816Phase 3Active
- Sponsor
- Zelgen
- Start
- Dec 2021
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of dalnacogene ponparvovec in hemophilia B (HB), sponsored by Zelgen. Started Dec 2021; status: active.
02
Drugs
dalnacogene ponparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on CTR20212816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212816.